Price
$0.6925
Increased by +1.84%
Dollar Volume (20D)
56.28 K
ADR%
10.18
Earnings Report Date (estimate)
Nov 1, 23 (0.26)
Market Cap.
6.02 M
Shares Float
5.39 M
Shares Outstanding
8.69 M
Beta
-0.40
Price / Earnings
-0.25
BPR
0.71
20D Range
0.54 0.86
50D Range
0.54 1.22
200D Range
0.54 2.35
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 10, 23 0.52
Increased by +157.78%
0.29
Increased by +79.31%
May 12, 23 -1.37
Decreased by -52.22%
-0.13
Decreased by -953.85%
Mar 30, 23 1.23
Increased by +236.67%
-0.15
Increased by +920.00%
Nov 15, 21 -0.75
Increased by +16.67%
-0.75
Aug 16, 21 -0.90
Increased by +45.45%
-0.90
May 17, 21 -0.90
Increased by +25.00%
-0.90
Mar 31, 21 -0.90
Increased by +81.82%
-0.90
Nov 4, 20 -0.90
Increased by +57.14%
-1.50
Increased by +40.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 0.00
Decreased by N/A%
-4.01 M
Decreased by -564.51%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-8.71 M
Decreased by -204.83%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
5.01 M
Increased by +176.57%
Increased by +N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-660.00 K
Increased by +24.23%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-603.00 K
Increased by +36.46%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-2.86 M
Decreased by -186.27%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-6.55 M
Decreased by -559.42%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-871.00 K
Increased by +15.27%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.